Research

Autoantibody Biomarker Discovery

H-Pylori – Parkinson’s Disease Study

Study Design:

  • Investigate the association of H-pylori in PD patients: 30 H. pylori-seropositive PD samples were designated as case and 30 age- and gender- matched H. pylori-seronegative PD samples were used as controls

Results:

  • Study identified 13 significant autoantibodies based on ranking using a penetrance fold change method.
  • Among elevated autoantibodies in H. pylori-seropositive PD, NFIA, PDGFB and eIFA3 are essential proteins involved in neurological function.

Published study:

Augmentation of Autoantibodies by Helicobacter pylori in Parkinson’s Disease Patients May Be Linked to Greater Severity

 

Fold changes between H. pylori-seropositive PD samples (Case) and H. pylori-seronegative (Control) groups for autoantibodies showing higher activity in the case group.

Drug Companion Diagnostics

Checkpoint Inhibitor Melanoma Trial

Study Design:

  • Metastatic melanoma, BRAF mutant patients, treated with either:
    1. Ipilimumab (anti-CTLA-4)
    2. Pembrolizumab (anti-PD-1)
    3. Nivolumab (anti-PD-1)
    4. Ipil & Nivo

Results:

  • ~58% response rate in nivo plus ipil patients, but high grade (3 or 4) irAEs occur in ~55%
  • The combination of nivolumab and ipilimumab resulted in numerically longer progression-free survival and a higher rate of response than did nivolumab alone in the overall study population
  • The incidence of adverse events in this study was, in general, lowest in the nivolumab group and highest in the combination group

Published study:

Autoantibodies May Predict Immune-Related Toxicity: Results from a Phase I Study of Intralesional Bacillus Calmette-Guérin followed by Ipilimumab in Patients with Advanced Metastatic Melanoma

Fold changes between H. pylori-seropositive PD samples (Case) and H. pylori-seronegative (Control) groups for autoantibodies showing higher activity in the case group.

Protein Interaction Assays

DNA-Protein Interaction Study

Study Design:

  • p53 microarray printed onto a neutravidin-derivatised dextran hydrogel surface probed with Cy3-labelled GADD45 duplex oligo

Results:

  • Quantitative parallel thermodynamic analysis revealed previously unknown functional effects of mutation on p53 protein-DNA interaction
  • Differential DNA binding activity of p53 mutant proteins
  • Quantitative analysis unravels mechanistic differences between ‘loss of function’ mutations 

Published study:

Functional protein microarrays for parallel characterisation of p53 mutants

Featured Products

IMMUNOME™

High-throughput platform of 1600+ immunomodulatory proteins

CTA array

High-throughput protein array of
200+ cancer-testis antigens

Custom array

Flexible miniaturised format for
high-throughput screening

1996 – 2018 © Sengenics All rights reserved | Sengenics Corporation Pte Ltd. Registered in Singapore no. 201734100D | Sengenics UK Ltd. Registered in England and Wales No 11016361 

X